Fondaparinux: does it cause HIT? can it treat HIT?

References

• Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost.68(1), 95–96 (1992).
   PubMed Web of Science ®Google Scholar
• Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N. Engl. J. Med.355(8), 809–817 (2006).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest133(6 Suppl.), S340–S380 (2008).
   PubMedGoogle Scholar
• Greinacher A, Gopinadhan M, Guenther JU et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler. Thromb. Vasc. Biol.26(10), 2386–2393 (2006).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb. Res.122(2), 211–220 (2008).
   PubMed Web of Science ®Google Scholar
• Rauova L, Poncz M, McKenzie SE et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood105(1), 131–138 (2005).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med.332(20), 1330–1335 (1995).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med.163(20), 2518–2524 (2003).
   PubMed Web of Science ®Google Scholar
• Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin prophylaxis: a meta-analysis. Blood106(8), 2710–2715 (2005).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood108(9), 2937–2941 (2006).
   PubMed Web of Science ®Google Scholar
• Turpie AG. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin. Pharmacother.5(6), 1373–1384 (2004).
   PubMed Web of Science ®Google Scholar
• Alban S, Greinacher A. Role of sulphated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia (4th Edition). Warkentin TE, Greinacher A (Eds). Informa Healthcare USA, NY, USA 167–186 (2007).
   Google Scholar
• Amiral J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul. Fibrinolysis8(2), 114–117 (1997).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cook RJ, Marder VJ et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood106(12), 3791–3796 (2005).
   PubMed Web of Science ®Google Scholar
• Elalamy I, Lecrubier C, Potevin F et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb. Haemost.74(5), 1384–1385 (1995).
   PubMed Web of Science ®Google Scholar
• Savi P, Chong BH, Greinacher A et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood105(1), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation post-orthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J. Thromb. Haemost.8(3), 504–512 (2010).
   PubMed Web of Science ®Google Scholar
• Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J. Thromb. Haemost.3(12), 2813–2815 (2005).
   PubMed Web of Science ®Google Scholar
• Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood112(7), 2607–2616 (2008).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann. Intern. Med.135(7), 502–506 (2001).
   PubMed Web of Science ®Google Scholar
• Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J. Thromb. Haemost.3(10), 2168–2175 (2005).
   PubMed Web of Science ®Google Scholar
• Socher I, Kroll H, Jorks S, Santoso S, Sachs UJ. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J. Thromb. Haemost.6(1), 197–200 (2008).
   PubMed Web of Science ®Google Scholar
• Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann. Intern. Med.136(3), 210–215 (2002).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N. Engl. J. Med.348(11), 1067–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Alsaleh KA, Al-Nasser SM, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset heparin-induced thrombocytopenia caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am. J. Hematol.83(11), 876–878 (2008).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N. Engl. J. Med.356(25), 2653–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb. Haemost.99(4), 779–781 (2008).
   PubMed Web of Science ®Google Scholar
• Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia (HIT) syndrome complicated by arterial thrombotic stroke. Thromb. Haemost. DOI: 10.1160/TH10-05-0284 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J. Thromb. Haemost.6(7), 1243–1246 (2008).
   Web of Science ®Google Scholar
• Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia in a patient treated with fondaparinux. Clin. Adv. Hematol. Oncol.8(1), 61–62 (2010).
   PubMedGoogle Scholar
• Chong BH, Chong JJH. Review: heparin-induced thrombocytopenia associated with fondaparinux. Clin. Adv. Hematol. Oncol.8(1), 63–65.
   PubMedGoogle Scholar
• Elalamy I, Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. J. Thromb. Haemost.6(7), 1242–1243 (2008).
   PubMed Web of Science ®Google Scholar
• Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Reponse to Rota et al. (Thromb. Haemost.99, 779–781 [2008]). Thromb. Haemost.100(1), 168–169 (2008).
   PubMed Web of Science ®Google Scholar
• Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT? J. Thromb. Haemost.6(9), 1598–1600 (2008).
   PubMed Web of Science ®Google Scholar
• Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT? J. Thromb. Haemost.7(3), 499–501 (2009).
   PubMed Web of Science ®Google Scholar
• DeSancho MT, Carlson KS, Mallik A. A case of spontaneous heparin induced thrombocytopenia and thrombosis. J. Thromb. Haemost. PP-WE-718 (2009) (Abstract).
   Google Scholar
• Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am. J. Med.121(7), 632–636 (2008).
   PubMed Web of Science ®Google Scholar
• Gruel Y, Pouplard C, Nguyen P et al. French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br. J. Haematol.121(5), 786–792 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol. Oncol. Clin. North Am.24(4), 755–775 (2010).
   PubMed Web of Science ®Google Scholar
• Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb. Haemost.93(5), 999–1000 (2005).
   PubMed Web of Science ®Google Scholar
• Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb. Haemost.99(1), 208–214 (2008).
   PubMed Web of Science ®Google Scholar
• Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin. Appl. Thromb. Hemost. DOI: 10.1177/1076029609347900 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Pappalardo F, Scandroglio A, Maj G, Zangrillo A, D’Angelo A. Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J. Thorac. Cardiovasc. Surg.139(3), 790–792 (2010).
   PubMed Web of Science ®Google Scholar
• Selleng S, Malowsky B, Strobel U et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia even when antibody tests are positive. J. Thromb. Haemost.8(1), 30–36 (2010).
   PubMed Web of Science ®Google Scholar
• Arixtra®, prescribing information. GlaxoSmithKline, NC, USA (2010).
   Google Scholar
• Baroletti S, Labreche M, Niles M, Fanikos J, Goldhaber SZ. Prescription of fondaparinux in hospitalised patients. Thromb. Haemost.101(6), 1091–1094 (2009).
   PubMed Web of Science ®Google Scholar
• D’Angelo A, Valle PD, Fattorini A, Crippa L. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thromb. Haemost.95(3), 573–575 (2006).
   PubMed Web of Science ®Google Scholar
• Filis K, Lagoudianakis EE, Pappas A et al. Heparin-induced thrombocytopenia and phlegmasia cerulean dolens of the upper limb: successfully treated with fondaparinux. Acta Haematol.120(3), 190–191 (2008).
   PubMed Web of Science ®Google Scholar
• Serasli E, Antoniadou M, Tsara V et al. Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia Type II (HIT II): a case series. Thromb. J.6, 9 (2008).
   PubMedGoogle Scholar
• Spyropoulos AC, Magnuson S, Koh SK. The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thrombocytopenia and thrombosis caused by heparin flushes. Ther. Clin. Risk Manag.4(3), 653–657 (2008).
   PubMedGoogle Scholar
• Thorsteinsson GS, Magnussson M, Hallberg LM et al. Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis. World J. Gastroenterol.14(28), 4576–4579 (2008).
   PubMed Web of Science ®Google Scholar
• Neykova A, Tzvetkov B, Merah AK, Matheron C, Kirsch M. The HIT treatment in a cardiac surgery patient. Int. J. Cardiol. DOI: 10.1016/j.ijcard.2009.03.027 (2009) (Epub ahead of print).
   Google Scholar
• Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (arixtra®), as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica88(11), ECR32 (2003).
   PubMedGoogle Scholar
• Sideris SK, Bonios MJ, Eftihiadis EE et al. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. Hellenic J. Cardiol.46(3), 242–246 (2005).
   PubMedGoogle Scholar
• Jankowski K, Ozdzenska-Milke E, Lichodziejewska B, Huba M, Ciurzyński M, Pruszczyk P. [Recurrent pulmonary embolism in a patient with heparin-induced thrombocytopenia]. Pol. Arch. Med. Wewn.117(11–12), 524–526 (2007).
   PubMedGoogle Scholar
• Nowicka A, Kandziora M, Szymanowska K et al. [Heparin-induced thrombocytopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfully treated with fondaparinux – a case report]. Kardiol. Pol.66(12), 1306–1308 (2008).
   PubMed Web of Science ®Google Scholar
• Akoum R, Mahfoud D, Ghaoui A et al. Budd-Chiari syndrome and heparin-induced thrombocytopenia in polycythemia vera: successful treatment with repeated TIPS and interferon a. J. Cancer Res. Ther.5(4), 305–308 (2009).
   PubMed Web of Science ®Google Scholar
• Seldrum S, Lambert M, Hainaut P. Heparin-induced thrombocytopenia successfully treated with fondaparinux. Acta Clin. Belg.64(2), 144–146 (2009).
   PubMed Web of Science ®Google Scholar
• Lapecorella M, Lucchesi A, Di Ianni M et al. Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia. Blood Coagul. Fibrinolysis21(1), 85–90 (2010).
   PubMed Web of Science ®Google Scholar
• D’Amico EA, Villaça PR, Gualandro SFM, Bassitt RP, Chamone DAF. Successful use of Arixtra® in a patient with paroxysmal nocturnal hemoglobinuria, Budd–Chiari syndrome and heparin-induced thrombocytopenia. J. Thromb. Haemost.1(11), 2452–2453 (2003).
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Rocktaeschel J et al. Use of fondaparinux (ARIXTRA®) in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II. Nephrol. Dial. Transplant.20(2), 444–446 (2005).
   PubMed Web of Science ®Google Scholar
• Holtan SG, Knox SK, Tefferi A. Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia. J. Thromb. Haemost.4(7), 1632–1634 (2006).
   PubMed Web of Science ®Google Scholar
• Gralec R, Dybowska M, Kuca P, Burakowski J, Tomkowski W. [Thrombocytopenia probably heparin-induced in woman with tumor of the heart and pulmonary embolism]. Pneumonol. Alergol. Pol.74(2), 216–220 (2006).
   PubMedGoogle Scholar
• Myzienski AE, Lutz MF, Smythe MA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy30(3), e105–e112 (2010).
   Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med.344(17), 1286–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Kohlmann T, Strobel U, Sheppard JI, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood113(20), 4970–4976 (2009).
   PubMed Web of Science ®Google Scholar
• Patterson SL, LaMonte MP, Mikdashi JA, Haines ST, Hursting MJ. Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature. Pharmacotherapy26(10), 1518–1525 (2006).
   PubMed Web of Science ®Google Scholar
• Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int. J. Obstet. Anesth.19(1), 82–87 (2010).
   PubMed Web of Science ®Google Scholar
• Maurer SH, Wilimas JA, Wang WC, Reiss UM. Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. Pediatr. Blood Cancer53(3), 468–471 (2009).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162(16), 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE; Apollo Investigators. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J. Thromb. Haemost.5(9), 1854–1861 (2007).
   PubMed Web of Science ®Google Scholar
• Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin. Ther.29(11), 2395–2405 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br. Med. J.332(7537), 325–329 (2006).
   PubMed Web of Science ®Google Scholar
• Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med.354(14), 1464–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al; OASIS-6 TRIAL Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA295(13), 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H et al; Matisse investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Ann. Intern. Med.140(11), 867–873 (2004).
   PubMed Web of Science ®Google Scholar
• Büller H, Davidson BL, Decousus H et al.; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349(18), 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica89(8), 1017–1018 (2004).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI. Testing for heparin-induced thrombocytopenia antibodies. Transfus. Med. Rev.20(4), 259–272 (2006).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Juhl D, Strobel U et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J. Thromb. Haemost.5(8), 1666–1673 (2007).
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J. Thromb. Haemost.9(8), 1260–1265 (2009).
   Google Scholar
• Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am. J. Hematol.82(12), 1037–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Wester JPJ, Leyte A, Oudemans-van Straaten HM et al. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth. J. Med.65(3), 101–108 (2007).
   PubMed Web of Science ®Google Scholar
• Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb. Haemost.85(6), 950–957 (2001).
   PubMed Web of Science ®Google Scholar
• Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet.41(Suppl. 2), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Sombolos KI, Fragia TK, Gionanlis LC et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int. J. Clin. Pharmacol. Ther.46(4), 198–203 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol.50(18), 1742–1751 (2007).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul. Fibrinolysis20(2), 114–121 (2009).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb. Haemost.99(5), 819–829 (2008).
   PubMed Web of Science ®Google Scholar
• Chong BH, Gallus AS, Cade FJ et al; Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb. Haemost.86(5), 1170–1175 (2001).
   PubMed Web of Science ®Google Scholar
• Fugate S, Chiappe J. Standardizing the management of heparin-induced thrombocytopenia. Am. J. Health Syst. Pharm.65(4), 334–339 (2008).
   PubMed Web of Science ®Google Scholar
• McIntyre KM, Warkentin TE. Legal aspects of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia (3rd Edition). Warkentin TE, Greinacher A (Eds). Marcel Dekker, NY, USA 573–585 (2004).
   Google Scholar
• US FDA Drug Bulletin 12, 4–5 (1982).
   Google Scholar